2024
Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk
McCoy R, Swarna K, Neumiller J, Polley E, Deng Y, Mickelson M, Herrin J. Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Clinical Diabetes 2024 DOI: 10.2337/cd24-0007.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2Moderate cardiovascular disease riskRisk of severe hypoglycemiaGlucose-lowering therapyCardiovascular disease riskType 2 diabetesSevere hypoglycemiaSodium-glucose cotransporter 2 inhibitorsDPP-4GLP-1 receptor agonistsGlucagon-like peptide 1Risk of hypoglycemiaDPP-4 inhibitorsDipeptidyl peptidase 4Disease riskAvoidance of hypoglycemiaSulfonylurea therapyReceptor agonistsCotransporter 2Sulfonylurea usePatient populationGLP-1Peptidase 4HypoglycemiaEmergency department
2015
Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010.
McCoy RG, Zhang Y, Herrin J, Denton BT, Mason JE, Montori VM, Smith SA, Shah ND. Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010. The American Journal Of Managed Care 2015, 21: e288-96. PMID: 26167776.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAge FactorsAgedBlood GlucoseComorbidityDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemic AgentsIncretinsInsurance Claim ReviewMaleMetforminMiddle AgedResidence CharacteristicsRetrospective StudiesSex FactorsSocioeconomic FactorsSulfonylurea CompoundsUnited StatesYoung AdultConceptsTreatment intensificationCox proportional hazards regression analysisNational administrative data setProportional hazards regression analysisRetrospective secondary data analysisDiabetes treatment intensificationOptimal diabetes careHazards regression analysisDiabetes-related complicationsAdults 18 yearsTreatment-naïve adultsNon-Hispanic whitesComorbidity burdenMetformin monotherapySulfonylurea useMetformin prescriptionThiazolidinedione useGlycemic controlKaplan-MeierMean ageDiabetes careSignificant confoundersSecondary data analysisAdministrative data setsDiabetes therapy